Comparison · NCT04393038-4e800de0
ABX464 vs Placebo: Rate of Patients Hospitalized
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ABX464 vs Placebo: Rate of Patients Hospitalized. Trial comparisons, record NCT04393038-4e800de0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04393038-4e800de0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.113 | 0.0767 | 0.164 | wilson | |
| Risk in group 2 | 0.108 | 0.0613 | 0.183 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00546 | -0.078 | 0.0745 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.533 | 2.07 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.494 | 2.26 | log | |
| Number needed to treat, for one more participant with the outcome on ABX464 than on Placebo | 183 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ABX464 | ABX464 50 mg once a day (oral capsule) for 28 days + Standard of Care (SOC) | 23 | 203 | OG000 |
| Group 2 | Placebo | Placebo 50 mg once a day (oral capsule) + Standard of Care (SOC) | 11 | 102 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rate of Patients Hospitalized
- Description
To evaluate the proportion of patients requiring hospitalization during the study compared to the {Standard of Care + placebo} group An interim analysis was triggered when the first 305 patients were randomized in the study. As the study was stopped for futility based on the interim analysis results, no efficacy data were collected for the patients who were randomized but not included in the interim analysis. Efficacy results are only available for the 305 patients randomized at the time of the interim analysis.
- Time frame
- 28 days
- Population
- Number of patients randomized at time of Interim analysis
Source ClinicalTrials.gov
Trial
- Title
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
- NCT number
- NCT04393038
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- ABX464, Placebo
- Lead sponsor
- Abivax S.A.
- Results first posted
- 2025-11-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04393038?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04393038-4e800de0